Newormics resumes operations

Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have resumed operations in our lab and in our manufacturing facility as of August 1st. This means we can now be contacted for purchasing our vivoCube system, accessory kits, and for obtaining more vivoChips for your Read more about Newormics resumes operations[…]

The Fast Team Uses the Worm

In a play on the adage “the early bird gets the worm”, Newormics describes how Perlara accelerated the search for a repurposed drug to treat an orphan disease using the microscopic soil worm, C. elegans.   Drug repurposing, once thought to be much less desirable than the development of new molecular entities for disease treatment, Read more about The Fast Team Uses the Worm[…]

vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office

Patent covers the vivoChip® invention that vivoVerse licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, TX. August 5, 2020 – vivoVerse (formerly operating as Newormics), a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models, announced that the European Patent Office (EPO) intends to grant a patent covering Read more about vivoVerse Announces Intent to Grant Utility Patent on the vivoChip® by the European Patent Office[…]

vivoVerse awarded SBIR Phase II grant from the NIMH

vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies. vivoVerse’s core focus is to facilitate the use of C. elegans as Read more about vivoVerse awarded SBIR Phase II grant from the NIMH[…]